Navigation Links
Oncolytics Biotech(R) Inc. Announces Issuance of 35th U.S. Patent
Date:6/17/2010

within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements, including among others, the Company's belief as to the importance of the issuance of this patent, the safety and efficacy of the reovirus, the Company's expectations as to the potential applications of the patented technology and other statements relating to anticipated developments in the Company's business and technologies, involve known and unknown risks and uncertainties that could cause the Company's actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties include, among others, the efficacy of REOLYSIN as a cancer treatment, the success and timely completion of clinical studies and trials, uncertainties related to the research and development of pharmaceuticals and uncertainties related to the regulatory process. Investors should consult the Company's quarterly and annual filings with the Canadian and U.S. securities commissions for additional information on risks and uncertainties relating to the forward-looking statements. Investors are cautioned against placing undue reliance on forward-looking statements. The Company does not undertake to update these forward-looking statements, except as required by applicable laws.


'/>"/>
SOURCE Oncolytics Biotech Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Oncolytics Biotech Inc. Announces Issuance of 23rd U.S. Patent
2. Oncolytics Biotech Inc. Reports Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
3. Media Advisory - Oncolytics Biotech Inc. to Present at BioPartnering Europe
4. Media Advisory - Oncolytics Biotech Inc. to Present at BIO InvestorForum 2007
5. Oncolytics Biotech Inc. Announces Approval for U.K. Clinical Trial Investigating REOLYSIN(R) in Combination with Cyclophosphamide
6. Oncolytics Biotech Inc. Collaborators to Present Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
7. Oncolytics Biotech Inc. Announces 2007 Third Quarter Results
8. Media Advisory - Oncolytics Biotech Inc. to Present at Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
9. Media Advisory - Oncolytics Biotech Inc. to Present at Toronto CFA Society
10. Oncolytics Biotech Inc. Announces Issuance of 24th U.S. Patent
11. Oncolytics Biotech Inc. to Present at Annual Vaccine Production Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2015)... , July 28, 2015 /PRNewswire/ - Aeterna Zentaris ... announced that it has granted to German life ... the development and commercialization of biotechnology (collectively, the ... recombinant oral allogenic tumor vaccine technology (the "Technology"), ... prostate cancer which is ready to enter a ...
(Date:7/28/2015)... July 28, 2015  Faced with increasing challenges ... palliative rather than symptomatic, the global healthcare industry ... therapies capable of curing or significantly changing the ... to look towards regenerative medicine as a viable ... paradigm in human health with the potential to ...
(Date:7/27/2015)... EDMONTON , July 27, 2015 /PRNewswire/ - Quest ... pharmaceutical company developing and commercializing products for the treatment ... Quest announces that it has closed a $1,000,000 ... private placement of 16,666,667 units of the Company at ... comprised of one common share and one common share ...
(Date:7/27/2015)... ... July 27, 2015 , ... Brady (NYSE:BRC), a ... 3 Ways to GHS Labels . This video provides useful information on ... (GHS) by effectively labeling chemical containers. , “With the fourth and final deadline ...
Breaking Biology Technology:Aeterna Zentaris Grants Option to Develop and Commercialize Oral Allogenic Cancer Vaccine Technology 2Aeterna Zentaris Grants Option to Develop and Commercialize Oral Allogenic Cancer Vaccine Technology 3Stem Cell Therapy to Redefine Regenerative Medicine, says Frost & Sullivan 2Stem Cell Therapy to Redefine Regenerative Medicine, says Frost & Sullivan 3Stem Cell Therapy to Redefine Regenerative Medicine, says Frost & Sullivan 4Stem Cell Therapy to Redefine Regenerative Medicine, says Frost & Sullivan 5Quest PharmaTech Closes $1,000,000 Private Placement 2Brady Releases “3 Roads to GHS Labels” Video 2
... (NYSE: MOS ) has announced it will ... taking place on Wednesday, February 9, 2011.  Larry Stranghoener, ... scheduled to speak at 10:10 a.m. Eastern Standard Time. ... be available at the time of the presentation on ...
... ROCHESTER, N.Y., Feb. 7, 2011 Thermal Gradient, a ... fast PCR technology for molecular diagnostics.  PCR (polymerase chain ... forms of DNA testing. The company,s latest ... the performance of PCR at speeds many times faster ...
... N.J., Feb. 7, 2011 ... today it will host a roundtable and give a ... week at the Summit for Clinical Ops Executives ( ... hotel. (Logo: http://photos.prnewswire.com/prnh/20100707/NY31446LOGO) As part ...
Cached Biology Technology:Thermal Gradient Announces Breakthrough in Fast PCR Device Technology 2Cmed Technology to Host Roundtable, Give Presentation About EDC Pain Points at Summit for Clinical Ops Executives (SCOPE) 2Cmed Technology to Host Roundtable, Give Presentation About EDC Pain Points at Summit for Clinical Ops Executives (SCOPE) 3
(Date:7/9/2015)... , July 07, 2015 ... the addition of the "Biometrics for Banking; ... 2015-2020" report to their offering. ... contributor to this growth and the forecast is ... in revenue for companies involved in delivering biometric ...
(Date:7/9/2015)... JOSE, Calif. , July 9, 2015 ... the leading developer of human interface solutions, ... technology, the industry,s first fully hardware encapsulated ... Match-in-Sensor secure authentication technology is literally off ... storage and biometric matching within the fingerprint ...
(Date:7/8/2015)... NEW YORK , July 8, 2015  BD ... announced BD & Guidepoint Mentor, a new ... to Guidepoint,s expert network services. BD ... technologies to improve healthcare delivery and outcomes and, with ... start-up entrepreneur will be able to directly engage with ...
Breaking Biology News(10 mins):Global Banking Biometrics Market 2015-2020 - Market & Technology Analysis, Adoption Strategies and Forecasts 2Global Banking Biometrics Market 2015-2020 - Market & Technology Analysis, Adoption Strategies and Forecasts 3Synaptics Announces World's First Match-in-Sensor Fingerprint Authentication Technology 2Synaptics Announces World's First Match-in-Sensor Fingerprint Authentication Technology 3BD and Guidepoint Team to Connect Healthcare Start-up Companies With Business and Scientific Experts 2BD and Guidepoint Team to Connect Healthcare Start-up Companies With Business and Scientific Experts 3
... A tiny, fast switch that uses water droplets to create ... mechanism found in palm beetles. , The new beetle-inspired ... on the scale of a micron -- a millionth of ... larger applications like powerful adhesive bonding. Like the transistor, whose ...
... that the brains of alcoholics are smaller, lighter ... speakers at the October 2004 Congress for the ... Mannheim, Germany reviewed what is known about the ... shrinkage. Proceedings are published in the June issue ...
... and Infectious Diseases (NIAID), part of the National Institutes ... which cause such serious diseases as West Nile fever, ... defenses in different ways depending on whether they are ... to new approaches to developing vaccines and treatments against ...
Cached Biology News:Beetle-inspired switch uses water for bonding 2Investigating 'brain shrinkage' in alcoholics 2Investigating 'brain shrinkage' in alcoholics 3Investigating 'brain shrinkage' in alcoholics 4Investigating 'brain shrinkage' in alcoholics 5Scientists show that tick-borne flaviviruses use a novel mechanism to evade host defenses 2Scientists show that tick-borne flaviviruses use a novel mechanism to evade host defenses 3
... materials necessary for the isolation and preparation of ... Kit Components: Erythrocyte ... containing 220 mL of buffered ammonium chloride. (NH ... No. 5113) One bottle containing 220 mL of ...
... culture systems provide an integrated ... for staining and imaging. Each ... preassembled with standard optical-quality coverslips ... entire system is provided sterile ...
ANTI NO-TRYPTOPHAN CONJUGATE...
... The Zero Background/Kan Cloning ... with kanamycin resistance for selection ... vector utilizes positive selection to ... contains all of the reagents ...
Biology Products: